Samsara BioCapital GP, LLC
Samsara BioCapital GP, LLC's purchase track record
How the stock did after each of Samsara BioCapital GP, LLC's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/13/2025 | MLYS | $8.10M | +10.5% | +175.3% | +19.3% |
| 11/26/2024 | NGNE | $1.26M | -37.6% | -36.4% | -1.7% |
| 2/12/2024 | MLYS | $7.50M | -12.2% | -23.0% | +6.4% |
| 10/16/2023 | SRRK | $15.00M | +92.6% | +61.4% | +15.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Neurogene Announces Inducement Grants Under Nasdaq Rules. Neurogene disclosed that it issued inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is typically used to attract or retain key personnel without requiring shareholder approval. The announcement provides context for the stock's current position near its support level, though no new financial results or clinical data were released in this update.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
VTVT Completes Phase 3 Cadisegliatin Trial Enrollment. vTv Therapeutics announced that enrollment for its phase 3 cadisegliatin trial in type 1 diabetes has been completed. The milestone moves the program closer to the next study stage and may influence future clinical and commercial outlook. The stock is currently trading near a long‑standing support level that has been tested many times.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Scholar Rock Refiles Apitegromab Application With EMA. Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.
Transaction History
| MLYS | ▲ Buy | Open Market | 600,000 | $8.1M | 3/13/2025 | View on chart |
| NGNE | ▲ Buy | Open Market | 20,748 | $517K | 11/26/2024 | View on chart |
| NGNE | ▲ Buy | Open Market | 10,803 | $281K | 11/26/2024 | View on chart |
| NGNE | ▲ Buy | Open Market | 15,219 | $407K | 11/26/2024 | View on chart |
| NGNE | ▲ Buy | Open Market | 2,000 | $55K | 11/26/2024 | View on chart |
| VTVT | ▼ Sell | Other | 58,836 | — | 3/5/2024 | View on chart |
| MLYS | ▲ Buy | Open Market | 555,555 | $7.5M | 2/12/2024 | View on chart |
| SRRK | ▲ Buy | Open Market | 2,189,781 | $15.0M | 10/16/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Mineralys Presents Phase 3 Data, Receives Mixed Analyst Views
Mineralys Therapeutics presented new data from its pivotal Phase 3 Launch-HTN study at the American Heart Association Hypertension Scientific Sessions 2026. Following this update, UBS initiated coverage with a Neutral rating and a $29 price target, while HC Wainwright reiterated a Buy rating with a $56 target. The stock is currently trading near its support level, reflecting the divided analyst opinions on the company's outlook.
Mineralys Presents Phase 3 Data, Receives Mixed Analyst Views. Mineralys Therapeutics presented new data from its pivotal Phase 3 Launch-HTN study at the American Heart Association Hypertension Scientific Sessions 2026. Following this update, UBS initiated coverage with a Neutral rating and a $29 price target, while HC Wainwright reiterated a Buy rating with a $56 target. The stock is currently trading near its support level, reflecting the divided analyst opinions on the company's outlook.